These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 16860974

  • 1. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D.
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [Abstract] [Full Text] [Related]

  • 2. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD, Andersen SW.
    J Clin Psychiatry; 1999 Sep; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [Abstract] [Full Text] [Related]

  • 3. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [Abstract] [Full Text] [Related]

  • 4. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO.
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [Abstract] [Full Text] [Related]

  • 5. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
    Masand P, O'Gorman C, Mandel FS.
    Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
    [Abstract] [Full Text] [Related]

  • 6. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr 13; 31(3):703-12. PubMed ID: 17289237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. On the concept of remission in schizophrenia.
    Leucht S, Beitinger R, Kissling W.
    Psychopharmacology (Berl); 2007 Nov 13; 194(4):453-61. PubMed ID: 17618422
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H, Osuntokun OO, Feldman PD.
    Compr Psychiatry; 2012 Jan 13; 53(1):107-15. PubMed ID: 21310400
    [Abstract] [Full Text] [Related]

  • 14. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.
    Sethuraman G, Taylor CC, Enerson M, Dunayevich E.
    Schizophr Res; 2005 Nov 15; 79(2-3):337-40. PubMed ID: 16054802
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ, Ascher-Svanum H, Adams DH, Chen L.
    J Clin Psychopharmacol; 2008 Oct 15; 28(5):544-9. PubMed ID: 18794651
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct 15; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 15; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.